SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Sarepta Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$17.73+0.63 (+3.68%)

Close on Oct 19, 2026

Market cap: $1.87B
P/E (TTM): –
Dividend yield: –

Sarepta Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	2,198	1,902	1,243	933	702	540	381	301	155	5.42	1.25	9.76	–	–	–	–	–
Cost of Revenue	26	–	–	–	–	–	–	–	–	0.13	–	–	–	–	–	–	–
Gross Profit	2,173	–	–	–	–	–	–	–	–	5.29	–	–	–	–	–	–	–
Research & Development	1,522	805	877	877	771	722	561	402	167	188	146	94	73	52	67	36	24
Selling, General & Admin	492	558	482	451	283	318	285	208	123	84	75	49	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	75	49	32	15	16	14	8.70
Advertising Expenses	30	32	29	15	7.70	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	–	–	–	–	–	–	221	144	105	67	–	–	–
Total Costs & Expenses	2,898	1,684	1,511	1,469	1,162	1,104	1,086	645	326	272	221	144	–	–	–	–	–
Operating Income	-700	218	-268	-536	-460	-564	-706	-344	-172	-267	-220	-134	-90	-30	-36	-21	-16
Interest Expense	-38	-18	-22	-53	64	60	31	34	5.80	1.89	1.37	0.10	0.10	0.10	0.10	0.09	–
Interest & Investment Income	31	31	36	16	0.35	2.97	7.24	6.81	1.81	0.51	0.89	–	–	–	–	–	–
Income from Equity Investments	0	0	-30	-2.58	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-2.44	43	-252	-154	41	11	-8.32	-19	123	-0.54	0.15	-2.00	-22	-92	34	-11	-9.65
Merger & Restructuring Charges	42	0	0	–	–	–	–	-2.22	3.02	4.56	–	0.01	0.76	0.19	1.15	–	–
Gain (Loss) on Investments	-16	-2.79	1.53	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	–	-3.94	-0.81	-0.29	-0.20	-0.13	-0.59	-0.36	-0.19	–	–
Pretax Income	-702	261	-520	-690	-419	-553	-714	-363	-49	-267	-220	–	–	–	–	–	–
Income Tax Expense	11	26	16	14	-0.17	1.06	1.20	-0.69	2.06	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	-713	235	-536	-703	-419	-554	-715	-362	-51	-267	–	–	–	–	–	–	–
Net Income	-713	235	-536	-703	-419	-554	-715	-362	-51	-267	-220	-136	-112	-121	-2.32	-32	-25
Net Income to Common	-713	235	-536	-703	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-7.13	2.47	-5.80	-8.03	-5.15	-7.11	-9.71	-5.46	-0.86	-5.49	-5.20	-3.39	-3.31	-5.14	-0.11	-1.74	-1.62
EPS (Diluted)(per share)	-7.13	2.34	-5.80	-8.03	-5.15	-7.11	-9.71	-5.46	-0.86	-5.49	-5.20	-3.39	-3.31	-5.14	-0.11	-1.74	-1.62
Shares Outstanding (Basic, Weighted)(shares)	100	95	92	88	81	78	74	66	59	49	42	40	34	24	22	19	16
Shares Outstanding (Diluted, Weighted)(shares)	100	108	92	88	81	78	74	66	59	49	42	40	34	24	22	19	16
EBITDA	-655	256	-223	-494	-422	-537	-681	-331	-164	-261	-215	-130	-89	-28	-35	-19	-14

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 110.0%
Operating margin: -7.3%
Net margin: -6.9%
Return on equity, FY2025: -53.5%

Financial strength

Current ratio: 4.42
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 113.6%

Valuation

P/E ratio: –
Price to sales: 0.95
Price to book: 1.22
Dividend yield: –